HCAT at a glance
Health Catalyst, Inc. (HCAT, SEC CIK 1636422) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Health Catalyst, Inc. (HCAT) reported revenue of $311.1 million (up 1.5% from FY2024) and a net loss of $178.0 million. Diluted EPS was -$2.55.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Health Catalyst, Inc. (HCAT) shares worth $11.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Landry Benjamin on November 12, 2026 of 29,478 shares at $1.39 per share.
- In the last 90 days, HCAT insiders reported 1 open-market purchase ($105K) and 2 open-market sales ($141K) on Form 4, a net sale of $36K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $311.1M
- +1.5% vs prior year
- Insiders · 90 days
- 1 buy · 2 sells
- Net −$36K
- 13F holders
- 23 funds
- $11.5M · +0 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $56.3M, down 26% YoY from $76.3M, driven by Vitalware divestiture and DOS-to-Ignite churn
- Total gross margin 31% vs 39% YoY; net income $40.5M vs $22.2M loss, including $65.9M Vitalware gain
- Technology revenue $40.7M, down 22%; professional services $15.6M, down 36%, the weaker segment
- Cash from operations $16.9M vs $9.2M used YoY; $144.5M Vitalware proceeds funded debt repayment
- Near-term headwinds: Medicaid cuts, elongated sales cycles, Ignite migration churn, and lower technology margins through 2027
Risk Factors
- Newly added regulatory risk: OBBBA Medicaid funding reductions enacted July 2025 could reduce enrollment and covered services
- Most material update: Project Nexus reduced global workforce approximately 7% by second quarter 2026, risking execution and employee attrition
- AI compliance risk: California, Colorado, Texas, and Utah enacted or advanced requirements affecting AI safeguards, disclosures, and accountability
- Near-term operating risk: DOS-to-Ignite migration continues causing client churn, downselling, and smaller bookings
- Financial concentration risk: Three largest clients represented 13.6% of 2025 revenue, increasing exposure to renegotiations or loss of major accounts
AI summary of the HCAT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 results released for quarter ended September 30, 2026
- Exhibit 99.1 contains Health Catalyst’s financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $56.3M, down 26% YoY after Vitalware divestiture and DOS-to-Ignite migration headwinds
- Adjusted EBITDA $0.8M, down 94% YoY, signaling sharply weaker underlying profitability despite cost reductions
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Tami Reller joins HCAT’s Board October 1, expanding director count from six to seven
- Reller becomes Audit Committee chair, replacing Justin Spencer, who remains on the committee
Item EX-99.1: Item EX-99.1
- Tami Reller appointed director effective October 1, 2026, adding healthcare, technology, finance, and public-company governance expertise
- Reller becomes audit chair and joins compensation committee, strengthening oversight during Health Catalyst’s leadership transition
Item 7.01: Regulation FD Disclosure
- Health Catalyst appointed Ms. Reller to its Board on September 14, 2026
- Board addition may influence governance, strategic oversight and shareholder confidence
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Simeon Kohl becomes CEO, President and director September 14, 2026, replacing Ben Albert
- Kohl brings prior CEO experience at Performant Healthcare and healthcare technology leadership
Item EX-99.1: Item EX-99.1
- Simeon Kohl becomes CEO, President, and director effective September 14, 2026
- Ben Albert transitions to Chief Business Officer and leaves the Board effective September 13, 2026
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 announces officer and director transitions at Health Catalyst
- Board plans RSU grants for Mr. Kohl tied to his appointments
AI summaries of HCAT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HCAT
Don't miss the next HCAT filing
- Alerts as it files. A push when HCAT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HCAT, by share count.
- Ask anything. An AI agent that reads every HCAT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Landry Benjamin | Sell | Nov 12, 2026 | 29,478 | $1.39 |
| Landry Benjamin | Sell | Nov 11, 2026 | 70,000 | $1.43 |
| Reller Tami | A | Oct 1, 2026 | 128,851 | - |
| Kohl Simeon | A | Sep 14, 2026 | 2,747,385 | - |
| Kohl Simeon | Buy | Sep 14, 2026 | 59,000 | $1.79 |
| Albert Benjamin | F | Sep 10, 2026 | 35,244 | $1.67 |
| Alger Jason | F | Sep 1, 2026 | 17,973 | $1.70 |
| Larson-Green Julie | A | Sep 1, 2026 | 9,766 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $306.6M | $311.1M |
| Operating Income | - | -$69.8M | -$160.9M |
| Net Income | -$118.1M | -$69.5M | -$178.0M |
| Op. Margin | - | -22.8% | -51.7% |
| Net Margin | - | -22.7% | -57.2% |
| Balance Sheet | |||
| Total Assets | - | $858.9M | $502.6M |
| Equity | $366.9M | $365.2M | $245.8M |
| ROE | -32.2% | -19.0% | -72.4% |
| Per Share | |||
| EPS | $-2.09 | $-1.15 | $-2.55 |
| Cash Flow | |||
| Operating CF | - | $14.6M | $731K |
| CapEx | $1.2M | $1.6M | $968K |
Source: XBRL data in Health Catalyst, Inc. (HCAT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate HCAT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $11.5M |
| Q2 2026 | 23 | $18.6M |
| Q1 2026 | 21 | $18.4M |
| Q4 2025 | 22 | $40.6M |
| Q3 2025 | 24 | $53.7M |
| Q2 2025 | 25 | $62.2M |
| Q1 2025 | 23 | $52.3M |
| Q4 2024 | 20 | $91.0M |
- Morgan Stanley+88.1K (+83%)
- JPMorgan Chase & Co+41.7K (+2139%)
- Vanguard Portfolio Management LLC+16.2K (+13%)
- Two Sigma Investments+13.0K (+95%)
- Bank of America Corp+9.0K (+17%)
- Dimensional Fund Advisors−717.2K (-79%)
- Renaissance Technologies LLC−269.7K (-77%)
- AQR Capital Management−267.2K (-71%)
- Goldman Sachs Group−251.5K (-52%)
- Millennium Management−248.8K (-48%)
- StoneX Group Inc.+10.5K
- FMR LLC (Fidelity)−410.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 181 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HCAT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 13, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 4 | Sep 11, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| SC 13G | Jul 21, 2026 | - | - | |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| SC 13D | Jun 22, 2026 | - | - | |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - |
Related Information Technology companies
- APP · AppLovinServices-Computer Programming, Data Processing, Etc.
- BLND · Blend Labs, Inc.Services-Computer Programming, Data Processing, Etc.
- BMBL · Bumble Inc.Services-Computer Programming, Data Processing, Etc.
- CEVA · CEVA INCServices-Computer Programming, Data Processing, Etc.
- DOCN · DigitalOcean Holdings, Inc.Services-Computer Programming, Data Processing, Etc.
- EVER · EverQuote, Inc.Services-Computer Programming, Data Processing, Etc.
- GDS · GDS Holdings LtdServices-Computer Programming, Data Processing, Etc.
- GRND · Grindr Inc.Services-Computer Programming, Data Processing, Etc.
HCAT SEC filings: frequently asked questions
Are HCAT insiders buying or selling?
In the last 90 days, Health Catalyst, Inc. (HCAT) officers, directors and 10% owners reported 1 open-market purchase worth $105,439 by 1 insider and 2 open-market sales worth $140,974 by 1 insider on Form 4, a net sale of $35,535. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold HCAT stock?
As of September 30, 2026, the largest Health Catalyst, Inc. (HCAT) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($4.8 million), BlackRock ($2.7 million), State Street Corp ($603,000), Millennium Management ($462,000), Goldman Sachs Group ($397,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HCAT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Health Catalyst, Inc. (HCAT) reported revenue of $311.1 million (up 1.5% from FY2024) and a net loss of $178.0 million. Diluted EPS was -$2.55. The figures come from the XBRL data in the 10-K.
What did HCAT report in its latest 8-K?
Health Catalyst, Inc. (HCAT) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results released for quarter ended September 30, 2026.
What are the latest HCAT SEC filings?
Health Catalyst, Inc. (HCAT) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.
What is HCAT's SEC CIK number?
Health Catalyst, Inc. (HCAT)'s SEC Central Index Key (CIK) is 1636422. EDGAR lists every HCAT filing under that number.
Ask anything about HCAT
The research agent reads HCAT's filings, financials, insider trades and 13F holders, then answers with sources.